The McManus Group represents some of the most notable
and respected health care companies and associations
in the country.

Alnylam Pharmaceuticals, headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on the discovery, development, and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. Alnylam’s pioneering work has delivered the world’s first and only approved RNAi therapeutics – Onpattro, Givlaari, and Oxlumo. Alnylam continues to advance a deep pipeline of innovative RNAi-based medicines in four therapeutic areas: genetic medicines, cardio-metabolic diseases, infectious diseases, and central nervous system (CNS) and ocular diseases.

Invivyd is a biopharmaceutical company on a mission to protect humans from serious viral diseases. The company is developing antibodies to transcend the limits of naturally occurring immunity to provide superior protection from viral diseases, beginning with COVID-19.

Avadel Pharmaceuticals is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options.

Gilead Sciences, Inc., located in Foster City, CA, is a research-based biopharmaceutical company that is a leader in treatments for HIV/AIDS, liver diseases, serious respiratory and cardiovascular conditions, cancer and inflammation. Gilead’s portfolio of 15 marketed products includes a number of category firsts, including the only complete treatment regiments for HIV infection available in a once-daily single pill. Gilead’s portfolio also includes Truvada, the first drug approved for HIV prevention in uninfected adults at high risk.

Headquartered in Seal Beach, California, Dendreon Pharmaceuticals develops immunotherapies to treat cancer. Its flagship product, Provenge, was the first FDA-approved immunotherapy made from a patient’s own immune cells. Since its approval in 2010, nearly 40,000 men with advanced prostate cancer have been treated with Provenge.

The Ambulatory Surgery Center Association represents more than 11,000 facilities and corporate ambulatory surgery centers (ASCs), which provide a less expensive and higher quality alternative for outpatient surgery than outpatient hospital departments.

MEDNAX, Inc. is a national medical group with over 3,100 partner facilities that comprise the nation’s leading providers of prenatal, neonatal, maternal-fetal and pediatric physician subspecialty services.

Royalty Pharma has created a rapidly growing company within the biopharmaceutical industry through the acquisition of revenue producing intellectual property – principally, royalty interests in marketed and late stage development biopharmaceutical products. Royalty Pharma has been working with research institutions, inventors and biotechnology & pharmaceutical companies since 1996 and now owns royalty interests in 36 approved and marketed biopharmaceutical products and 9 products in clinical trials and/or under review with the United States Food and Drug Administration (“FDA”) and/or the European Medicines Agency (“EMA”).

The Digestive Health Physicians Association (DHPA) represents 96 independent gastroenterology (GI) physician practices and over 2,300 physicians with the aim of promoting and preserving accessible, high quality and cost-efficient care in the independent GI medical practice setting.

The American Occupational Therapy Association (AOTA) represents the interests and concerns of 230,000 occupational therapy practitioners and students. AOTA’s major programs and activities are directed toward assuring the quality of occupational therapy services, improving consumer access to healthcare services, and promoting the professional development of members.

Founded in 2008, The Large Urology Group Practice Association (LUPGA) represents independent urology physician practices that provide comprehensive and integrated urological care for patients with prostate cancer, bladder cancer, and other ailments.

The National Association of Freestanding Emergency Centers (NAFEC) represents the spectrum of FECs, including independent, hospital-owned, and hybrid models alike. They were established to advocate for fair regulation and to raise statewide awareness of freestanding emergency centers as a high-quality, accessible, emergency medical care option.

Formed in 1958, PhRMA, the Pharmaceutical Research and Manufacturers of America, represents leading innovative research-based biopharmaceutical companies in the US. Since 2000, PhRMA member companies have invested nearly $1 trillion in the search for new treatments and cures, including an estimated $83 billion in 2019 alone.

Horizon Therapeutics is a global biopharmaceutical company focused on researching, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs for people impacted by rare and rheumatic diseases. Horizon’s products include Duexis to relieve arthritic pain and prevent gastric ulcers, Vimovo to relieve arthritic pain and ankylosing spondylitis, and Tepezza to treat thyroid eye disease.

The Infusion Providers Alliance (IPA) is the leading voice for providers of drug infusion services in this outpatient setting of care and leads an effort to preserve the integrity of the doctor-patient relationship in a manner that delivers exceptional care to patients at a lower cost to the health care system. The IPA represents infusion providers with over 930 locations in more than 42 states across the U.S. Collectively, the IPA members administer more than 640,000 treatments annually.

Located in South San Francisco, Genentech is a leader in cancer care with treatments including Avastin, Actemra, Tacerva, Lucentis, Erivedge, PERJETA, and Kadcyla. Now owned by Roche Holdings, the company employs nearly 14,000 people.

EMD Serono, Inc. is a German-based company with more than 1,300 employees throughout the United States headquartered in Rockland, Massachusetts. With a deep expertise in neurology, fertility, and endocrinology, EMD Serono has a strong pipeline with more than 20 trials in their global clinical pipeline. Projects include potential new oncology and immuno-oncology medicines as well as therapeutic options for psoriasis, lupus, multiple sclerosis, and other autoimmune diseases.

Zimmer Biomet, headquartered in Warsaw, Indiana, is a global leader in musculoskeletal healthcare. They design, manufacture and market orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products.

Founded in 1992, The Medical Device Manufacturers Association (MDMA) is a national trade association based in Washington, DC providing educational and advocacy assistance to more than 270 innovative and entrepreneurial medical technology companies. MDMA is the leading voice representing the interests of innovative and entrepreneurial medical technology companies.

Based in Menlo Park, CA, GRAIL is a clinical-stage diagnostics company developing a multi-cancer blood test for detection of more than 50 types of cancer across early and late stages. The test also aims to detect an individual’s cancer tissue of origin to guide physicians and patients toward a faster, more efficient, and most appropriate treatment.

At WEX Health, we simplify the business of healthcare. We do that through WEX Health Cloud, a cloud-based healthcare financial management platform that drives efficiency for benefit administration technology, consumer engagement, and advanced billing and payments. Our network of partner organizations enables us to deliver our industry-leading and award-winning solution to 343,000 employers and more than 28 million consumers across the United States, Canada, South America, Europe, Asia and Australia. Together we take the complexity out of defined contribution, HSAs, HRAs, FSAs, VEBAs, PRAs, premium billing, public and private health insurance exchanges, COBRA, wellness plans, and transit plans.

Founded in 1998, PTC Therapeutics is a U.S. biopharmaceutical company headquartered in South Plainfield, New Jersey. PTC is focused on the innovative development of orally administered small molecule and gene therapies which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in rare genetic disorders. PTC operates in offices and/or research labs in more than 20 countries and occupies a footprint in more than 50 countries around the world. PTC has recently expanded its therapeutic areas from solely genetic disorders into oncology and virology therapeutic research.

Orchard Therapeutics is a global gene therapy leader dedicated to transforming the lives of people affected by severe diseases through the development of innovative, potentially curative gene therapies. Our exvivo autologous gene therapy approach harnesses the power of genetically modified blood stem cells and seeks to correct the underlying cause of disease in a single administration. In 2018, Orchard acquired GSK’s rare disease genetherapy portfolio, which originated from a pioneering collaboration between GSK and the San Raffaele Telethon Institute for Gene Therapy in Milan, Italy. Orchard now has one of the deepest and most advanced gene therapy product candidate pipelines in the industry spanning multiple therapeutic areas where the disease burden on children, families and caregivers is immense and current treatment options are limited or do not exist. Orchard has its global headquarters in London and U.S. headquarters in Boston.

Current clients include the following (please contact our office for a complete client list):


The McManus Group
610 10th St. NW
Washington , DC , 20001
(817) 876-2045